INFIQ — Infinity Pharmaceuticals Share News
0.000.00%
Last trade - 00:00IndustrialsHighly SpeculativeMicro Cap
- $0.00m
- -$17.75m
- $2.59m
Infinity Pharmaceuticals Inc reports results for the quarter ended in December - Earnings Summary
Infinity Pharmaceuticals Inc expected to post a loss of 13 cents a share - Earnings Preview
Infinity Pharmaceuticals Inc expected to post a loss of 13 cents a share - Earnings Preview
Brief: Infinity Pharmaceuticals Outlines Eganelisib Clinical Development Strategy and Provides 2022 Guidance
Brief: Infinity Pharmaceuticals Says Selected For Addition To Nasdaq Biotechnology Index
U.S. STOCKS ON THE MOVE-General Motors, AMC Entertainment, Oracle, Costco
Infinity Pharma rises after promising data from cancer therapy study
Brief: Infinity Pharmaceuticals Inc Encouraging Updated Data From Phase 2 MARIO-3 TNBC Trial Presented At 2021 San Antonio Breast Cancer Symposium
Brief: Infinity Pharmaceuticals Posts Q3 Loss Per Share Of $0.12
Infinity Pharmaceuticals Inc expected to post a loss of 13 cents a share - Earnings Preview
U.S. STOCKS ON THE MOVE-Square, Affirm, Foot Locker, Tesla, Robinhood
U.S. STOCKS ON THE MOVE-Square, Foot Locker, Immunovant, Bloomin' Brands, Affirm
JPM upgrades Infinity Pharma to "overweight" on cancer drug potential
U.S. RESEARCH ROUNDUP- Aon, Charter Communications, Mastercard
U.S. RESEARCH ROUNDUP-Five9, Globant SA, Monolithic Power Systems
Brief: Infinity Pharmaceuticals Reports Q2 Loss Per Share Of $0.13
Brief: Infinity Pharmaceuticals - Have Entered Into Amendment To Amended, Restated Capital On Demand Sales Agreement, Dated July 29, 2019
Infinity Pharmaceuticals Inc reports results for the quarter ended in June - Earnings Summary
Brief: Infinity Pharmaceuticals Presents Updated Data From Phase 2 Mario-275 Trial In Urothelial Cancer (Uc) And Phase 2 Mario-3 Trial In Triple Negative Breast Cancer (Tnbc)